Researchers Studying Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed, Refractory AML
Phase: Recruiting
First Posted: February
Condition(s): Acute Myeloid Leukemia (AML)
NCT Number: NCT05503134 Other Study ID Number(s): KARMA
What Is the Purpose of This Study?
To determine the safety and recommended phase II dose of adoptive NK cell therapy using UD-NK cells.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Patients with relapsed or primary refractory acute myeloid leukemia (AML)
- Age 1-24.99 years
For a full list of eligibility requirements, visit https://www.clinicaltrials.gov/study/NCT05503134
What Will Happen During This Study?
Patients will receive up to 2 cycles of therapy. Each cycle of therapy will consist of:
- Fludarabine on Day -6 to Day -2
- Cytarabine on Day -6 to Day -2
- NK cells 3x weekly for 2 weeks for a total of 6 doses
Principal Investigator
Discover More Research
Explore additional studies relating to cell therapyYour Might Also Be Interested In
Research and Clinical Care: How They Work Together to Treat Children
In this 700 Children's blog post for parents, Nationwide Children's highlights how clinical research and clinical care work together as a key part of our strategic plan to achieve the best outcomes for children. Before delving into these elements work together, the post covers the basics of clinical research.
Leukemia (ALL and AML)
Leukemia (ALL and AML) is the most common form of childhood cancer. It affects the tissues of the body which make the blood cells and the bone marrow. When leukemia strikes, the body makes an abundance of abnormal white cells that invade the marrow and crowd out the normal healthy blood cells.